Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors
S. C. Sivakumaren, H. Shim, T. Zhang, F. M. Ferguson, M. R. Lundquist, C. M. Browne, H.-S. Seo, M. N. Paddock, T. D. Manz, B. Jiang, M.-F. Hao, P. Krishnan, D. G. Wang, T. J. Yang, N. P. Kwiatkowski, , N. S. Gray
This study identifies THZ-P1-2, a covalent pan-PI5P4K inhibitor, showing efficacy in AML/ALL cell lines and autophagy disruption, supporting PI5P4Ks as therapeutic targets in cancer.
bioRxiv · Oct 25, 2019Cancer Biology